Drug evaluation: tagatose in the treatment of type 2 diabetes and obesity.
Current opinion in investigational drugs London England 2000 (2006)
- PubMed: 17086938
Available from www.scopus.com
or
Abstract
Spherix Inc (formerly Biospherics) is developing tagatose, an orally active lactose derivative for the potential treatment of obesity and type 2 diabetes. The compound is also under investigation for the potential treatment of anemia, hemophilia and medical problems related to infertility, birth weight and excessive maternal food intake. Phase I and II clinical trials have been completed.
Readership Statistics
2 Readers on Mendeley
by Discipline
50% Chemistry
by Academic Status
100% Ph.D. Student
by Country
50% India
50% Germany
Sign up today - FREE
Mendeley saves you time finding and organizing research. Learn more
- All your research in one place
- Add and import papers easily
- Access it anywhere, anytime
